Craig J. Burd, Ph.D. - Publications

Affiliations: 
2006 University of Cincinnati, Cincinnati, OH 
Area:
Molecular Biology, Cell Biology

18 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Lavender CA, Cannady KR, Hoffman JA, Trotter KW, Gilchrist DA, Bennett BD, Burkholder AB, Burd CJ, Fargo DC, Archer TK. Downstream Antisense Transcription Predicts Genomic Features That Define the Specific Chromatin Environment at Mammalian Promoters. Plos Genetics. 12: e1006224. PMID 27487356 DOI: 10.1371/journal.pgen.1006224  0.44
2015 Patterson AR, Mo X, Shapiro A, Wernke KE, Archer TK, Burd CJ. Sustained reprogramming of the estrogen response after chronic exposure to endocrine disruptors. Molecular Endocrinology (Baltimore, Md.). 29: 384-95. PMID 25594248 DOI: 10.1210/me.2014-1237  0.44
2014 Young NA, Wu LC, Burd CJ, Friedman AK, Kaffenberger BH, Rajaram MV, Schlesinger LS, James H, Shupnik MA, Jarjour WN. Estrogen modulation of endosome-associated toll-like receptor 8: an IFNα-independent mechanism of sex-bias in systemic lupus erythematosus. Clinical Immunology (Orlando, Fla.). 151: 66-77. PMID 24525049 DOI: 10.1016/j.clim.2014.01.006  0.44
2013 Augello MA, Burd CJ, Birbe R, McNair C, Ertel A, Magee MS, Frigo DE, Wilder-Romans K, Shilkrut M, Han S, Jernigan DL, Dean JL, Fatatis A, McDonnell DP, Visakorpi T, et al. Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes. The Journal of Clinical Investigation. 123: 493-508. PMID 23257359 DOI: 10.1172/JCI64750  0.44
2012 Burd CJ, Ward JM, Crusselle-Davis VJ, Kissling GE, Phadke D, Shah RR, Archer TK. Analysis of chromatin dynamics during glucocorticoid receptor activation. Molecular and Cellular Biology. 32: 1805-17. PMID 22451486 DOI: 10.1128/MCB.06206-11  0.44
2011 Comstock CE, Augello MA, Schiewer MJ, Karch J, Burd CJ, Ertel A, Knudsen ES, Jessen WJ, Aronow BJ, Knudsen KE. Cyclin D1 is a selective modifier of androgen-dependent signaling and androgen receptor function. The Journal of Biological Chemistry. 286: 8117-27. PMID 21212260 DOI: 10.1074/jbc.M110.170720  0.44
2009 Comstock CE, Augello MA, Benito RP, Karch J, Tran TH, Utama FE, Tindall EA, Wang Y, Burd CJ, Groh EM, Hoang HN, Giles GG, Severi G, Hayes VM, Henderson BE, et al. Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5338-49. PMID 19706803 DOI: 10.1158/1078-0432.CCR-08-2865  0.44
2009 Schiewer MJ, Morey LM, Burd CJ, Liu Y, Merry DE, Ho SM, Knudsen KE. Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer Oncogene. 28: 1016-1027. PMID 19079343 DOI: 10.1038/onc.2008.446  0.44
2008 Wang Y, Dean JL, Millar EK, Tran TH, McNeil CM, Burd CJ, Henshall SM, Utama FE, Witkiewicz A, Rui H, Sutherland RL, Knudsen KE, Knudsen ES. Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists. Cancer Research. 68: 5628-38. PMID 18632615 DOI: 10.1158/0008-5472.CAN-07-3170  0.44
2008 Olshavsky NA, Groh EM, Comstock CE, Morey LM, Wang Y, Revelo MP, Burd C, Meller J, Knudsen KE. Cyclin D3 action in androgen receptor regulation and prostate cancer. Oncogene. 27: 3111-21. PMID 18084330 DOI: 10.1038/sj.onc.1210981  0.44
2006 Burd CJ, Morey LM, Knudsen KE. Androgen receptor corepressors and prostate cancer. Endocrine-Related Cancer. 13: 979-94. PMID 17158750 DOI: 10.1677/erc.1.01115  0.44
2006 Burd CJ, Petre CE, Morey LM, Wang Y, Revelo MP, Haiman CA, Lu S, Fenoglio-Preiser CM, Li J, Knudsen ES, Wong J, Knudsen KE. Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation Proceedings of the National Academy of Sciences of the United States of America. 103: 2190-2195. PMID 16461912 DOI: 10.1073/pnas.0506281103  0.44
2005 Link KA, Burd CJ, Williams E, Marshall T, Rosson G, Henry E, Weissman B, Knudsen KE. BAF57 governs androgen receptor action and androgen-dependent proliferation through SWI/SNF Molecular and Cellular Biology. 25: 2200-2215. PMID 15743818 DOI: 10.1128/MCB.25.6.2200-2215.2005  0.44
2005 Petre-Draviam CE, Williams EB, Burd CJ, Gladden A, Moghadam H, Meller J, Diehl JA, Knudsen KE. A central domain of cyclin D1 mediates nuclear receptor corepressor activity. Oncogene. 24: 431-44. PMID 15558026 DOI: 10.1038/sj.onc.1208200  0.44
2005 Burd CJ, Petre CE, Moghadam H, Wilson EM, Knudsen KE. Cyclin D1 binding to the androgen receptor (AR) NH2-terminal domain inhibits activation function 2 association and reveals dual roles for AR corepression. Molecular Endocrinology (Baltimore, Md.). 19: 607-20. PMID 15539430 DOI: 10.1210/me.2004-0266  0.44
2003 Petre-Draviam CE, Cook SL, Burd CJ, Marshall TW, Wetherill YB, Knudsen KE. Specificity of cyclin D1 for androgen receptor regulation. Cancer Research. 63: 4903-13. PMID 12941814  0.44
2003 Liby K, Neltner B, Mohamet L, Burd C, Ben-Jonathan N. Endostatin expression by MDA-MB-435 breast cancer cells effectively inhibits tumor growth. Cancer Biology & Therapy. 2: 48-52. PMID 12673115  0.44
2002 Farr CD, Burd C, Tabet MR, Wang X, Welsh WJ, Ball WJ. Three-dimensional quantitative structure-activity relationship study of the inhibition of Na(+),K(+)-ATPase by cardiotonic steroids using comparative molecular field analysis. Biochemistry. 41: 1137-48. PMID 11802712 DOI: 10.1021/bi011511g  0.44
Show low-probability matches.